Advertisement

PharmacoEconomics

, Volume 9, Issue 6, pp 517–524 | Cite as

A Cost Analysis of Alprostadil in Liver Transplantation

  • Dean G. Smith
  • Keith S. Henley
  • Carl S. Remmert
  • Steven L. Hass
  • Darrell A. CampbellJr
  • I. Douglas McLaren
Original Research Article

Summary

Alprostadil (prostaglandin Ei) administration to liver transplant recipients has been shown to result in a significant reduction in the duration of hospital admission for transplantation, and in the need for re-operations (other than re-transplants) and renal support. To study the economic impact of this finding, we examined data from a controlled trial for all single-transplant surviving patients (42 alprostadil, 49 controls) for whom complete billing records were available for transplant days -2 to +150. All costs were measured in 1992 US dollars.

Patients given alprostadil had lower total charges [mean ± standard deviation (SD) $US175 297 ± $US70 652] than patients given placebo (mean ± SD $US225 672 ± $US187 208) [p = 0.043]. The data suggest that the use of alprostadil may have a significant favourable impact on the cost of liver transplantation.

Keywords

Liver Transplantation Adis International Limited Orthotopic Liver Transplantation Professional Service Liver Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Hospital Association (AHA). Transplants — 1993. AHA News 1994 Jul 4; 30: 2Google Scholar
  2. 2.
    Hockerstedt K. Liver transplantation: a changing concept. Trans Proc 1994; 26: 1706–1707Google Scholar
  3. 3.
    Henderson JM, Gilmore GT, Hooks MA, et al. Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg 1992; 216: 248–254PubMedCrossRefGoogle Scholar
  4. 4.
    Busuttil RW, Shaked A, Millis JM, et al. One thousand liver transplants: the lessons learned. Ann Surg 1994; 219: 490–497PubMedCrossRefGoogle Scholar
  5. 5.
    Kania AJ. Market memo: transplant study supports centers of excellence. Health Care Strateg Manag 1993; 11: 18–23Google Scholar
  6. 6.
    Pageaux GP, Souche B, Perney P, et al. Results and cost of orthotopic liver transplantation for alcoholic cirrhosis. Trans Proc 1993; 25: 1135–1136Google Scholar
  7. 7.
    Evans RW. Expenditures and the role of financial incentives. JAMA 1993; 269: 3113–3118PubMedCrossRefGoogle Scholar
  8. 8.
    Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation: costs, insurance coverage and reimbursement. Gastroenterol Clin North Am 1993; 22: 451–473PubMedGoogle Scholar
  9. 9.
    Muto P, Freeman RB, Haug CE, et al. Liver transplant candidate stratification systems: implications for third-party payors and organ allocation. Transplantation 1994; 57: 306–308PubMedCrossRefGoogle Scholar
  10. 10.
    Staschak S, Wagner S, Block G, et al. A cost comparison of liver transplantation with FK506 or CyA as the primary immunosuppressive agent. Trans Proc 1990; 22: 47–49Google Scholar
  11. 11.
    Tancharoen S, Jones RM, Agnus PW, et al. Beneficial effect of prostaglandin Ei on hepatic allograft rejection following orthotopic liver transplantation. Trans Proc 1993; 25: 2890–2891Google Scholar
  12. 12.
    Himmelreich G, Hundt K, Bechstein WO, et al. Influence of prostaglandin Ei on hemostasis in orthotopic liver transplantation. Semin Thromb Hemost 1993; 19: 273–278PubMedCrossRefGoogle Scholar
  13. 13.
    Takaya S, Iwaki Y, Starzl TE. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids and prostaglandin Ej. Transplantation 1992; 54: 927–929PubMedCrossRefGoogle Scholar
  14. 14.
    Takaya S, Bronsther O, Abu-Elmagd K. Use of prostaglandin Ei in crossmatch-negative liver transplant recipients treated with FK506. Trans Proc 1993; 25: 2381–2385Google Scholar
  15. 15.
    Henley KS, Lucey MR, Normolle DP, et al. A double-blind placebo-controlled randomized trial of prostaglandin Ei in liver transplantation. Hepatology 1995; 21: 366–372PubMedGoogle Scholar
  16. 16.
    Sheiner PA. Prostaglandins in liver transplantation [editorial]. Hepatology 1995; 21: 592–593PubMedCrossRefGoogle Scholar
  17. 17.
    Merion RM, Bockenstedt PL, McLaren ID, et al. Mechanism of action of prostaglandin Ei in liver transplantation (OLT) [abstract]. Meetings of the American Gastroenterologic Association and the American Association for the Study of Liver Diseases at Digestive Disease Week; 1995; San DiegoGoogle Scholar
  18. 18.
    Finkler SA. The distinction between costs and charges. Ann Intern Med 1982; 96: 101–109Google Scholar
  19. 19.
    Takaya S, Doyle H, Todo S, et al. Reduction of primary non-function with prostaglandin Ei after clinical liver transplantation. Trans Proc 1995; 27: 1862–1867Google Scholar
  20. 20.
    Doyle HR, Marino IR, Jabbour N, et al. Early death or retransplantation in adults after orthotopic liver transplantation: can outcome be predicted? Transplantation 1994; 57: 1028–1036PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 1996

Authors and Affiliations

  • Dean G. Smith
    • 1
  • Keith S. Henley
    • 2
  • Carl S. Remmert
    • 3
  • Steven L. Hass
    • 4
  • Darrell A. CampbellJr
    • 2
  • I. Douglas McLaren
    • 2
  1. 1.Department of Health Management and Policy, School of Public HealthUniversity of MichiganAnn ArborUSA
  2. 2.University of Michigan Medical School, University of MichiganAnn ArborUSA
  3. 3.University of Michigan Hospitals, University of MichiganAnn ArborUSA
  4. 4.The Upjohn CompanyKalamazooUSA

Personalised recommendations